Mechanisms of action of topical therapies and the rationale for combination therapy

Journal of the American Academy of Dermatology

Volumn 53, Issue 1 SUPPL., 2005, Pages

  Norris, David A ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN INHIBITOR; CALCIPOTRIOL; COLECALCIFEROL DERIVATIVE; CORTICOSTEROID; LACTIC ACID; RETINOID; SALICYLIC ACID; TACROLIMUS; TAZAROTENIC ACID; ULOBETASOL PROPIONATE; UNCLASSIFIED DRUG;

ATOPIC DERMATITIS; BURNING SENSATION; CLINICAL PRACTICE; CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; HUMAN; PATIENT ATTITUDE; PRIORITY JOURNAL; PSORIASIS; REVIEW; SIDE EFFECT;

EID: 20444487290     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2005.04.027     Document Type: Article

References (62)

1. M. Lebwohl Combination, rotational, and sequential therapy G.D. Weinstein A.B. Gottlieb Therapy of moderate-to-severe psoriasis 2003 Marcel Dekker New York 179 195
2. R.C. Cornell, and R.B. Stoughton Correlation of the vasoconstriction assay and clinical activity in psoriasis Arch Dermatol 121 1985 63 67
3. R.C. Cornell Clinical trials of topical corticosteroids in psoriasis: correlations with the vasoconstrictor assay Int J Dermatol 31 Suppl 1 1992 38 40
4. J. Hughes, and M. Rustin Corticosteroids Clin Dermatol 15 1997 715 721
5. R.I. Scheinman, P.C. Cogswell, A.K. Lofquist, and A.S. Baldwin Jr. Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids Science 270 1995 283 286
6. N. Auphan, J.A. DiDonato, C. Rosette, A. Helmberg, and M. Karin Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis Science 270 1995 286 290
7. I.J. Elenkov, and G.P. Chrousos Stress hormones, proinflammatory and antiinflammatory cytokines, and autoimmunity Ann N Y Acad Sci 966 2002 290 303
8. W.Y. Almawi, and H. Tamim Posttranscriptional mechanisms of glucocorticoid antiproliferative effects: glucocorticoids inhibit IL-6-induced proliferation of B9 hybridoma cells Cell Transplant 10 2001 161 164
9. W.Y. Almawi, M.L. Lipman, A.C. Stevens, B. Zanker, E.T. Hadro, and T.B. Strom Abrogation of glucocorticoid-mediated inhibition of T cell proliferation by the synergistic action of IL-1, IL-6, and IFN-gamma J Immunol 146 1991 3523 3527
10. J.S. Goodwin, D. Atluru, S. Sierakowski, and E.A. Lianos Mechanism of action of glucocorticosteroids. Inhibition of T cell proliferation and interleukin 2 production by hydrocortisone is reversed by leukotriene B4 J Clin Invest 77 1986 1244 1250
11. S.B. Kim, W.S. Yang, O.S. Lee, K.P. Lee, J.S. Park, and D.S. Na Lipocortin-1 inhibits proliferation of cultured human mesangial cells Nephron 74 1996 39 44
12. W.Y. Almawi, M.S. Saouda, A.C. Stevens, M.L. Lipman, C.M. Barth, and T.B. Strom Partial mediation of glucocorticoid antiproliferative effects by lipocortins J Immunol 157 1996 5231 5239
13. M. Brunetti, A. Colasante, N. Mascetra, M. Piantelli, P. Musiani, and F.B. Aiello IL-10 synergizes with dexamethasone in inhibiting human T cell proliferation J Pharmacol Exp Ther 285 1998 915 919
14. B.P. Peters, F.G. Weissman, and M.A. Gill Pathophysiology and treatment of psoriasis Am J Health Syst Pharm 57 2000 645 659 quiz 660-1
15. D.G. Stewart, and H.M. Lewis Vitamin D analogues and psoriasis J Clin Pharm Ther 21 1996 143 148
16. A.M. Jensen, M.B. Llado, L. Skov, E.R. Hansen, J.K. Larsen, and O. Baadsgaard Calcipotriol inhibits the proliferation of hyperproliferative CD29 positive keratinocytes in psoriatic epidermis in the absence of an effect on the function and number of antigen-presenting cells Br J Dermatol 139 1998 984 991
17. S. Nagpal, J. Lu, and M.F. Boehm Vitamin D analogs: mechanism of action and therapeutic applications Curr Med Chem 8 2001 1661 1679
18. E. Lee, S.H. Jeon, J.Y. Yi, Y.J. Jin, and Y.S. Son Calcipotriol inhibits autocrine phosphorylation of EGF receptor in a calcium-dependent manner, a possible mechanism for its inhibition of cell proliferation and stimulation of cell differentiation Biochem Biophys Res Commun 284 2001 419 425
19. B. Patel, S. Siskin, R. Krazmien, and M. Lebwohl Compatibility of calcipotriene with other topical medications J Am Acad Dermatol 38 1998 1010 1011
20. R.A. Chandraratna Tazarotene: the first receptor-selective topical retinoid for the treatment of psoriasis J Am Acad Dermatol 37 Suppl 1997 S12 S17
21. R.A. Chandraratna Rational design of receptor-selective retinoids J Am Acad Dermatol 39 Suppl 1998 S124 S128
22. K.P. Callis, and G.G. Krueger Topical agents in the treatment of moderate-to-severe psoriasis G.D. Weinstein A.B. Gottlieb Therapy of moderate-to-severe Psoriasis 2nd ed. 2003 Marcel Dekker New York 29 51
23. S. Nagpal, S. Patel, A.T. Asano, A.T. Johnson, M. Duvic, and R.A. Chandraratna Tazarotene-induced gene 1 (TIG1), a novel retinoic acid receptor-responsive gene in skin J Invest Dermatol 106 1996 269 274
24. S. Nagpal, S. Patel, H. Jacobe, D. DiSepio, C. Ghosn, and M. Malhotra Tazarotene-induced gene 2 (TIG2), a novel retinoid-responsive gene in skin J Invest Dermatol 109 1997 91 95
25. M. Duvic, B. Helekar, C. Schulz, M. Cho, C. Hager, and DiSepio Expression of a retinoid-inducible tumor suppressor, Tazarotene-inducible gene-3, is decreased in psoriasis and skin cancer Clin Cancer Res 6 2000 3249 3259
26. D. DiSepio, C. Ghosn, R.L. Eckert, A. Deucher, N. Robinson, and M. Duvic Identification and characterization of a retinoid-induced class II tumor suppressor/growth regulatory gene Proc Natl Acad Sci U S A 95 1998 14811 14815
27. M. Duvic, S. Nagpal, A.T. Asano, and R.A. Chandraratna Molecular mechanisms of tazarotene action in psoriasis J Am Acad Dermatol 37 Suppl 1997 S18 S24
28. M. Duvic, A.T. Asano, C. Hager, and S. Mays The pathogenesis of psoriasis and the mechanism of action of tazarotene J Am Acad Dermatol 39 Suppl 1998 S129 S133
29. E. Bornhovd, W.H. Burgdorf, and A. Wollenberg Macrolactam immunomodulators for topical treatment of inflammatory skin diseases J Am Acad Dermatol 45 2001 736 743
30. G.R. Crabtree Calcium, calcineurin, and the control of transcription J Biol Chem 276 2001 2313 2316
31. G.S. Hamilton, and J.P. Steiner Immunophilins: beyond immunosuppression J Med Chem 41 1998 5119 5143
32. Protopic [package insert]. Deerfield (IL): Fujisawa Healthcare; 2000.
33. G. Michel, C. Ried, and A. Beetz FK-506 blocks expression of interleukin-8 receptor in normal human keratinocytes J Invest Dermatol 100 1993 449A
34. A. Panhans-Gross, N. Novak, S. Kraft, and T. Bieber Human epidermal Langerhans' cells are targets for the immunosuppressive macrolide tacrolimus (FK506) J Allergy Clin Immunol 107 2001 345 352
35. A. Wollenberg, S. Sharma, D. von Bubnoff, E. Geiger, J. Haberstok, and T. Bieber Topical tacrolimus (FK506) leads to profound phenotypic and functional alterations of epidermal antigen-presenting dendritic cells in atopic dermatitis J Allergy Clin Immunol 107 2001 519 525
36. A. de Paulis, C. Stellato, R. Cirillo, A. Ciccarelli, A. Oriente, and G. Marone Anti-inflammatory effect of FK-506 on human skin mast cells J Invest Dermatol 99 1992 723 728
37. M. Lebwohl, A. Menter, J. Koo, and S. Feldman Combination therapy to treat moderate to severe psoriasis J Am Acad Dermatol 50 2003 416 430
38. U. Wahn, J.D. Bos, M. Goodfield, R. Caputo, K. Papp, and A. Manjra Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children Pediatrics 110 2002 e2
39. M. Meurer, R. Folster-Holst, G. Wozel, G. Weidinger, M. Junger, and M. Brautigam Pimecrolimus cream in the long-term management of atopic dermatitis in adults: a six-month study Dermatology 205 2002 271 277
40. A. Kapp, K. Papp, A. Bingham, R. Folster-Holst, J.P. Ortonne, and P.C. Potter Long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti-inflammatory drug J Allergy Clin Immunol 110 2002 277 284
41. M. Lahfa, U. Mrowietz, M. Koenig, and J.C. Simon Calcitriol ointment and clobetasol propionate cream: a new regimen for the treatment of plaque psoriasis Eur J Dermatol 13 2003 261 265
42. R. Kaufmann, A.J. Bibby, R. Bissonnette, R. Cambazard, A.C. Chu, and J. Decroix A new calcipotriol/betamethasone dipropionate formulation (Daivobet) is an effective once-daily treatment for psoriasis vulgaris Dermatology 205 2002 389 393
43. L. Guenther, P.C. Van de Kerkhof, E. Snellman, K. Kragballe, A.C. Chu, and E. Tegner Efficacy and safety of a new combination of calcipotriol and betamethasone dipropionate (once or twice daily) compared to calcipotriol (twice daily) in the treatment of psoriasis vulgaris: a randomized, double-blind, vehicle-controlled clinical trial Br J Dermatol 147 2002 316 323
44. S. Singh, D.C. Reddy, and S.S. Pandey Topical therapy for psoriasis with the use of augmented betamethasone and calcipotriene on alternate weeks J Am Acad Dermatol 43 2000 61 65
45. K. Kragballe, L. Barnes, K.J. Hamberg, P. Hutchinson, F. Murphy, and D. Moller Calcipotriol cream with or without concurrent topical corticosteroid in psoriasis: tolerability and efficacy Br J Dermatol 139 1998 649 654
46. W.S. Douglas, Y. Poulin, J. Decroix, J.P. Ortonne, U. Mrowietz, and W. Gulliver A new calcipotriol/betamethasone formulation with rapid onset of action was superior to monotherapy with betamethasone dipropionate or calcipotriol in psoriasis vulgaris Acta Derm Venereol 82 2002 131 135
47. J.P. Ortonne, R. Kaufmann, M. Lecha, and M. Goodfield Efficacy of treatment with calcipotriol/betamethasone dipropionate followed by calcipotriol alone compared with tacalcitol for the treatment of psoriasis vulgaris: a randomised, double-blind trial Dermatology 209 2004 308 313
48. P.C. van de Kerkhof The impact of a two-compound product containing calcipotriol and betamethasone dipropionate (Daivobet/Dovobet) on the quality of life in patients with psoriasis vulgaris: a randomized controlled trial Br J Dermatol 151 2004 663 668
49. M.M. van Rossum, P.E. van Erp, and P.C. van de Kerkhof Treatment of psoriasis with a new combination of calcipotriol and betamethasone dipropionate: a flow cytometric study Dermatology 203 2001 148 152
50. L. Molin, T.P. Cutler, I. Helander, B. Nyfors, and N. Downes Comparative efficacy of calcipotriol (MC903) cream and betamethasone 17-valerate cream in the treatment of chronic plaque psoriasis. A randomized, double-blind, parallel group multicentre study. Calcipotriol Study Group Br J Dermatol 136 1997 89 93
51. M. Lebwohl, S.B. Siskin, W. Epinette, D. Breneman, T. Funicella, and R. Kalb A multicenter trial of calcipotriene ointment and halobetasol ointment compared with either agent alone for the treatment of psoriasis J Am Acad Dermatol 35 1996 268 269
52. M. Lebwohl, A. Yoles, K. Lombardi, and W. Lou Calcipotriene ointment and halobetasol ointment in the long-term treatment of psoriasis: effects on the duration of improvement J Am Acad Dermatol 39 1998 447 450
53. K.A. Papp, L. Guenther, B. Boyden, F.G. Larsen, R.J. Harvima, and J.J. Guilhou Early onset of action and efficacy of a combination of calcipotriene and betamethasone dipropionate in the treatment of psoriasis J Am Acad Dermatol 48 2003 48 54
54. M. Lebwohl, and Y. Poulin Tazarotene in combination with topical corticosteroids J Am Acad Dermatol 39 Suppl 1998 S139 S143
55. K.H. Kaidbey, J.W. Petrozzi, and A.M. Kligman Treatment of psoriasis with topically applied tretinoin and steroid ointment Arch Dermatol 111 1975 1001 1003
56. C.E. Orfanos, H.W. Schmidt, G. Mahrle, H. Gartmann, and W.F. Lever Retinoic acid in psoriasis: its value for topical therapy with and without corticosteroids. Clinical, histological nd electron microscopical studies on forty-four hospitalized patients with extensive psoriasis Br J Dermatol 88 1973 167 182
57. M.G. Lebwohl, D.L. Breneman, B.S. Goffe, J.R. Grossman, M.R. Ling, and J. Milbauer Tazarotene 0.1% gel plus corticosteroid cream in the treatment of plaque psoriasis J Am Acad Dermatol 39 1998 590 596
58. L.C. Guenther, Y.P. Poulin, and D.M. Pariser A comparison of tazarotene 0.1% gel once daily plus mometasone furoate 0.1% cream once daily versus calcipotriene 0.005% ointment twice daily in the treatment of plaque psoriasis Clin Ther 22 2000 1225 1238
59. E.A. Tanghetti An observation study evaluating the treatment of plaque psoriasis with tazarotene gels, alone and with an emollient and/or corticosteroid Cutis 66 2000 4 11
60. P.H. Bowman, J.E. Maloney, and J.Y. Koo Combination of calcipotriene (Dovonex) ointment and tazarotene (Tazorac) gel versus clobetasol ointment in the treatment of plaque psoriasis: a pilot study J Am Acad Dermatol 46 2002 907 913
61. T. Nakahara, T. Koga, S. Fukagawa, H. Uchi, and M. Furue Intermittent topical corticosteroid/tacrolimus sequential therapy improves lichenification and chronic papules more efficiently than intermittent topical corticosteroid/emollient sequential therapy in patients with atopic dermatitis J Dermatol 31 2004 524 528
62. H.M. Torok, R. Maas-Irslinger, and R.M. Slayton Clocortolone pivalate cream 0.1% used concomitantly with tacrolimus ointment 0.1% in atopic dermatitis Cutis 72 2003 161 166